Cancer Research

Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.

Cancer Research Products Areas

Products for Cancer Research - Page 39

Cat.No. Product Name Information/Activity
BCC6245 Pam3CSK4 Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2.
BCC6138 Poly(I:C) 24939-03-5
BCC4073 Resiquimod (R-848) Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
BCC7460 RWJ 21757 Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist.
BCC5603 C34 TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis.
BCC6320 CU CPT 22 CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with a Ki of 0.41 µM. CU-CPT22 blocks Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 µM.
BCC6319 CU CPT 4a 1279713-77-7
BCC5560 Hydroxychloroquine Sulfate Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial drug which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling.
BCC5203 VGX-1027 VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.
BCC6158 680C91 163239-22-3